BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The ASH abstracts, which were submitted on August 3, 2019, were released online this morning. The conference will take place in Orlando, FL, from December 7-10, 2019.
The SB-525 poster will show updated Alta study data including durability of Factor VIII (FVIII) levels, bleeding rate, factor usage, and safety, for all five patients in the high dose cohort of 3e13 vg/kg, with approximately 4 months to 11 months of follow-up after treatment with SB-525.
As of the abstract submission date, four patients in the 3e13 vg/kg cohort achieved FVIII levels within the normal range with no bleeding events reported up to 24 weeks post-administration. These patients did not require FVIII replacement therapy following the initial prophylactic period of up to approximately 3 weeks post-SB-525 administration. The fifth patient in the 3e13 vg/kg cohort had only recently undergone treatment with SB-525 at the time of the abstract submission. As previously reported, one patient had treatment-related serious adverse events (SAEs) of hypotension and fever, which occurred approximately 6 hours after completion of the vector infusion and resolved with treatment within 24 hours, with no loss of FVIII expression. SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer.
The rapid kinetics of Factor VIII expression, durability of response, and the relatively low intra-cohort variability in the context of a complete cessation of bleeding events and elimination of exogenous Factor VIII usage continues to suggest SB-525 is a differentiated hemophilia A gene therapy, said Bettina Cockroft, M.D., M.B.A., Chief Medical Officer of Sangamo, commenting on the published abstract. We are pleased with the progress of the program toward a registrational Phase 3 study led by Pfizer, who announced it has enrolled its first patient in the 6-month Phase 3 lead-in study. We have recently completed the manufacturing technology transfer to Pfizer and initiated the transfer of the IND.
Ex Vivo Gene-Edited Cell Therapy
The ST-400 beta thalassemia poster will show preliminary results from the first three patients enrolled in the Phase 1/2 THALES study. In this study, hematopoietic stem progenitor cells (HSPCs) are apheresed from the patient, edited to knock out the erythroid specific enhancer of the BCL11A gene, and cryopreserved prior to infusion back into the patient following myeloablative conditioning with busulfan. The first three patients all have severe beta thalassemia genotypes: 0/0, homozygous for the severe + IVS-I-5 (G>C) mutation, and 0/+ genotype including the severe IVS-II-654 (C>T) mutation, respectively.
As of the abstract submission date, Patient 1 and Patient 2 had experienced prompt hematopoietic reconstitution. Patient 1 had increasing fetal hemoglobin (HbF) fraction that contributed to a stable total hemoglobin. After being free from packed red blood cell (PRBC) transfusions for 6 weeks, the patient subsequently required intermittent transfusions. Patient 2 had rising HbF levels observed through 90 days post-infusion. For both patients, as of the most recent follow-up reported in the abstract, on-target insertions and deletions (indels) were present in circulating white blood cells. Patient 3 had just completed ST-400 manufacturing at the time of abstract submission. As previously disclosed, Patient 1 experienced an SAE of hypersensitivity during ST-400 infusion considered by the investigator to be related to the product cryoprotectant, DSMO, and which resolved by the end of the infusion. No other SAEs related to ST-400 have been reported and all other AEs have been consistent with myeloablation. No clonal hematopoiesis has been observed. Longer follow-up will be required to assess the clinical significance of these early results. ST-400 is being developed as part of a global collaboration between Sangamo and Sanofi, along with support through a grant from the California Institute for Regenerative Medicine (CIRM).
The first three patients enrolled in the THALES study all have severe beta thalassemia genotypes that result in almost no endogenous beta globin production. The increases in fetal hemoglobin and presence of on-target indels in circulating blood cells suggests successful editing using zinc finger nucleases. The results are preliminary and will require additional patients and longer-term follow-up to assess their clinical significance, said Adrian Woolfson, BM., B.Ch., Ph.D., Head of Research and Development. It is important to note that myeloablative hematopoietic stem cell transplantation reboots the hematopoietic system, and that sufficient time is required for the stem cells to fully repopulate the marrow and for new blood cells to form. In other myeloablative conditioning studies in a similar patient population, full manifestation of the effects of gene modification in the red blood cell compartment has taken as long as 12 months or more to become evident.
Sanofis in vitro sickle cell disease poster details a similar approach to ST-400, using mobilized HSPCs from normal donors and SCD patients and utilizing the same zinc finger nuclease for gene editing, delivered as transient non-viral RNA, and designed to disrupt the erythroid specific enhancer of the BCL11A gene, which represses the expression of the gamma globin genes, thereby switching off HbF synthesis. Results from ex vivo studies demonstrated enriched biallelic editing, increased HbF, and reduced sickling in erythroid cells derived from non-treated sickle cell disease patients. Sanofi has initiated a Phase 1/2 trial evaluating BIVV003, an ex vivo gene-edited cell therapy using ZFN gene editing technology to modify autologous hematopoietic stem cells using fetal hemoglobin to produce functional red blood cells with higher BhF content that are resistant to sickling in patients with severe sickle cell disease. Recruitment is ongoing.
About the Alta study
The Phase 1/2 Alta study is an open-label, dose-ranging clinical trial designed to assess the safety and tolerability of SB-525 gene therapy in patients with severe hemophilia A. SB-525 was administered to 11 patients in 4 cohorts of 2 patients each across 4 ascending doses (9e11 vg/kg, 2e12 vg/kg, 1e13vg/kg and 3e13vg/kg) with expansion of the highest dose cohort by 3 additional patients. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy (RMAT) designations to SB-525, which also received Orphan Medicinal Product designation from the European Medicines Agency.
About the THALES study
The Phase 1/2 THALES study is a single-arm, multi-site study to assess the safety, tolerability, and efficacy of ST-400 autologous hematopoietic stem cell transplant in 6 patients with transfusion-dependent beta thalassemia (TDT). ST-400 is manufactured by ex vivo gene editing of a patient's own (autologous) hematopoietic stem cells using non-viral delivery of zinc finger nuclease technology. The THALES study inclusion criteria include all patients with TDT (0/0 or non- 0/0) who have received at least 8 packed red blood cell transfusions per year for the two years before enrollment in the study. The FDA has granted Orphan Drug status to ST-400.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements regarding the Company's ability to develop and commercialize product candidates to address genetic diseases with the Company's proprietary technologies, as well as the timing of commencement of clinical programs and the anticipated benefits therefrom. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the outcomes of clinical trials, the uncertain regulatory approval process, uncertainties related to the execution of clinical trials, Sangamo's reliance on partners and other third-parties to meet their clinical and manufacturing obligations, and the ability to maintain strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable product candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission and Sangamo's most recent Quarterly Report on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
- The Wet AMD Gene Therapy Race - Adverum Biotechnologies Vs. Regenxbio - Seeking Alpha - June 5th, 2020
- Cell and gene therapies - Lexology - May 28th, 2020
- Bicoastal startup Kriya Therapeutics to grow gene therapy manufacturing in NC - WRAL Tech Wire - May 28th, 2020
- Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy | DNA RNA and Cells | News Channels - PipelineReview.com - May 28th, 2020
- Troubleshooting the Development of New Gene Therapies - Technology Networks - May 28th, 2020
- Lab Mice Shed Fat and Build Muscle with Gene Therapy - The Great Courses Daily News - May 28th, 2020
- Reversing SHANK3 mutations in mice mitigates autism-like traits - Spectrum - May 28th, 2020
- Orchard Therapeutics to Present at Virtual Investor Conferences in June - Yahoo Finance UK - May 28th, 2020
- Gene Therapy market worldwide is projected to grow by US$3.3 Billion - GlobeNewswire - May 28th, 2020
- Generation Bio tees up $125M IPO to push next-gen gene therapies - FierceBiotech - May 27th, 2020
- Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy - PRNewswire - May 27th, 2020
- Novartis' gene therapy approved in Europe, talks ongoing on price - BioPharma-Reporter.com - May 27th, 2020
- NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product - Business Wire - May 27th, 2020
- Evox Therapeutics Appoints Martin Andrews as Non-Executive Director - BioSpace - May 27th, 2020
- New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy - FiercePharma - May 27th, 2020
- Gene therapy could help millions of ash trees fight deadly beetle Emerald Ash Borer - inews - May 27th, 2020
- Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq - Xconomy - May 27th, 2020
- European regulators accept FibroGen's anemia drug for review; Passage Bio's lead gene therapy gets more love from the FDA - Endpoints News - May 27th, 2020
- QPS Continues to Expand UPLC-HRMS Quantitation Capabilities to Support Gene Therapy and Protein Drug Development - PRNewswire - May 19th, 2020
- Novartis wins conditional EU approval for gene therapy Zolgensma - Reuters - May 19th, 2020
- The Roller Coaster of Gene Therapy... - Labiotech.eu - May 19th, 2020
- Gene therapy reduces fat and builds muscle in mice - BioNews - May 19th, 2020
- Forget ExerciseThese Mice Got Ripped With Gene Therapy - Singularity Hub - May 19th, 2020
- UPDATED: Pfizer gene therapy ups levels of dystrophin expression in Duchenne trial but another safety setback mars results - Endpoints News - May 19th, 2020
- Thermo Fisher to invest $180M in new gene therapy plant - BioPharma Dive - May 19th, 2020
- Beam Therapeutics Taking Novel Approach to Gene Therapy - Yahoo Finance - May 19th, 2020
- Gene-Therapy Treatments for Tay-Sachs, Sickle Cell to Be Featured in Online Gathering - Barron's - May 19th, 2020
- Sarepta And Dyno Therapeutics Will Develop Next-Gen Gene Therapy Vectors - Contract Pharma - May 19th, 2020
- New gene therapy cuts fat and builds muscle with ease. But theres a catch - Digital Trends - May 19th, 2020
- New Gene Therapy Promises You Will Get Ripped Without Stepping in a Gym - Interesting Engineering - May 19th, 2020
- Merck KGaA adds to gene therapy manufacturing boom with 100M facility in California - Endpoints News - May 19th, 2020
- Japan's health insurance to cover 167 million gene therapy drug - The Japan Times - May 19th, 2020
- COVID 19 PANDEMIC: Gene Therapy Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty - May 19th, 2020
- Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a... - May 19th, 2020
- Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania - GlobeNewswire - May 11th, 2020
- Orgenesis sees 1Q revenue rocket driven by its Cell and Gene Therapy Biotech platform - Proactive Investors USA & Canada - May 11th, 2020
- Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat dietinduced obesity - Science Advances - May 11th, 2020
- BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases - Endpoints News - May 11th, 2020
- BioLife Solutions to Report First Quarter 2020 Financial Results and Provide Business Update on May 14th, 2020 - Chinook Observer - May 11th, 2020
- Adverum soars on early gene therapy data; BerGenBio raises 45.4M on the heels of Covid-19 move - Endpoints News - May 11th, 2020
- Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings - PRNewswire - May 11th, 2020
- Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies -... - May 11th, 2020
- Study suggests effective fat-reducing therapy - Tech Explorist - May 11th, 2020
- Senti Biosciences to Present on Gene Circuit-Based Therapies at the 2020 ASGCT Annual Meeting - Business Wire - May 11th, 2020
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... - May 11th, 2020
- Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis,... - May 11th, 2020
- UPDATE Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting - GlobeNewswire - May 11th, 2020
- This Gene Is a Molecular "Knob" That Fine-tunes Our Cortex's Electrical Activity - Technology Networks - May 11th, 2020
- Gene Therapy for Rare Disease Market 2020 Coronavirus (Covid-19) Business Impact 2026 Growth Trends by Manufacturers, Regions, Type and Application,... - May 11th, 2020
- Can gene therapy help develop coronavirus vaccine? Researchers banking on this technology for breakthrough - MEAWW - May 11th, 2020
- A Tribute to Max Randell, Gene Therapy Pioneer - PLoS Blogs - April 27th, 2020
- Merck KGaA to spend $110M on new gene therapy facility in California - BioPharma Dive - April 27th, 2020
- Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies |... - April 27th, 2020
- Glaucoma can be successfully treated with gene therapy - Telangana Today - April 27th, 2020
- Regenxbio Is A Leader In Gene Therapies - A Case Where The Platform Is Worth More Than The Pipeline - Seeking Alpha - April 27th, 2020
- UK Startup to Manufacture Cell and Gene Therapies with... - Labiotech.eu - April 27th, 2020
- Sangamo- Early-Stage Progress in Gene Therapy - Yahoo Finance - April 27th, 2020
- Inclusive Comprehension 2020: Gene Therapy Market (Trending PDF) Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - Jewish Life... - April 27th, 2020
- Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020 - Yahoo Finance - April 27th, 2020
- Lysogene S.A. (EPA:LYS): When Will It Breakeven? - Simply Wall St - April 27th, 2020
- Diabetes reversed in mice with genetically edited stem cells derived from patients - Washington University School of Medicine in St. Louis - April 27th, 2020
- Addressing the potential impact of coronavirus disease (COVID-19) on Hemophilia Gene Therapy Market: Quantitative Analysis from 2019 to 2025 to Enable... - April 27th, 2020
- COVID-19 impact: Gene Therapy Market 2019 Business Insights,Top Companies,Growth, Market Size Global Market Share, Trends, Outlook, Opportunity and... - April 27th, 2020
- Gene Therapy For Inherited Genetic Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 27th, 2020
- Glaucoma Could Be Successfully Treated With Gene Therapy - Technology Networks - April 26th, 2020
- Reversing diabetes with CRISPR and patient-derived stem cells - FierceBiotech - April 26th, 2020
- Glaucoma can be successfully treated with gene therapy - International Business Times, Singapore Edition - April 26th, 2020
- AskBio acquires BrainVectis to expand its gene therapy portfolio - News.MarketSizeForecasters.com - April 26th, 2020
- 'We're really at a tipping point': COVID-19 brings research into other medical conditions to a grinding halt - CBC.ca - April 26th, 2020
- ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on... - April 26th, 2020
- Gene Therapy Market : Global Outlook and Forecast 2020-2025 - Surfacing Magazine - April 26th, 2020
- Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status - Monthly Prescribing Reference - March 26th, 2020
- Redpin bags A round to advance Chantix-controlled gene therapies - FierceBiotech - March 26th, 2020
- Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies - BioSpace - March 26th, 2020
- Avectas and Vycellix Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies - BioSpace - March 26th, 2020
- Global Viral Vector and Plasmid DNA Manufacturing Market to Surpass US$ 2,205.6 Million by 2027 - CMI - Yahoo Finance - March 26th, 2020
- Codexis and Takeda partner on gene therapies for rare diseases - Pharmaceutical Technology - March 26th, 2020
- Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives - Yahoo Finance - March 26th, 2020
- Study reveals gene therapy may help in treating cardiac disease - The Siasat Daily - March 26th, 2020
- TCR therapy an attractive alternative to CAR T for immunotherapy - Drug Target Review - March 26th, 2020